Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need
Executive Summary
New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need.
You may also be interested in...
Copay Accumulator Programs Allowed In 2023 Private Insurance Market In Proposed Rule
Commercial payer programs to undercut manufacturer cost sharing assistance for drugs may continue next year under proposed rule released by the Centers for Medicare and Medicaid Services.
Drug Discount Programs Create More Cloud In Quest For Transparency
Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices.
Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021
Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.